Genky DrugStores Co., Ltd.
FY June 2026 Q3 Earnings Presentation Materials
For the third quarter of FY June 2026, net sales were 52,449 million yen (YoY +7.9%), and operating income was 2,304 million yen (YoY +2.7%), nearly in line with the plan.
Key Figures
- Net Sales (Q3 Results): 52,449 million yen (YoY +7.9%)
- Operating Income (Q3 Results): 2,304 million yen (YoY +2.7%)
- Full-year Net Sales Forecast: 221,200 million yen (YoY +10.2%)
AI要約
Overview of Performance
For the third quarter of FY June 2026, net sales amounted to 52,449 million yen (YoY +7.9%) and operating income was 2,304 million yen (YoY +2.7%). Sales fell short of the plan by approximately 0.8%, but operating income reached the planned level. Same-store sales improved toward the latter half of Q3, with customer traffic steadily increasing by +1.5% YoY. Gross profit margin was almost on plan with a slight 0.1 point decrease compared to the plan. Selling, general and administrative expenses increased due to higher personnel and utility costs, but were contained by stable operation of self-checkout registers and a work transfer system.
Outlook and Plans
Full-year earnings forecast projects net sales of 221,200 million yen (YoY +10.2%) and operating income of 11,050 million yen (YoY +14.4%). Three new large-scale stores are planned to open during the fiscal year, with eight closures. The company aims to enhance profitability by balancing gross profit margin and SG&A expenses while maintaining price competitiveness. EPS is forecast at 257.5 yen, with a target ROE of 14.5%.
Net Sales Trend (FY2024 to FY2026 Q3)
Operating Income Trend (FY2024 to FY2026 Q3)
Gross Profit Margin Trend (FY2024 to FY2026 Q3)
SG&A Expense Ratio Trend (FY2024 to FY2026 Q3)
Operating Margin Trend (FY2024 to FY2026 Q3)
Genky DrugStores Co., Ltd.
Company overview · Stock price · Financial data · All IR